Kinetic Patterns of Candida Albicans Germ Tube Antibody in Critically Ill Patients: Influence on Mortality

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2009 Aug 14

PMID 19675223

Citations 5

Authors

Rafael Zaragoza

Javier Peman

Guillermo Quindos

Jose R Iruretagoyena

Maria S Cuetara

Paula Ramirez

Maria D Gomez

Juan J Camarena

Angel Viudes

Jose Ponton

Affiliations

Soon will be listed here.

Abstract

The influence of kinetic patterns of Candida albicans germ tube antibodies (CAGTA) on mortality was analyzed in six intensive care units. Statistically significant lower mortality rates were found in patients with patterns of increasing CAGTA titers who had been treated with antifungal agents. Thus, antifungal treatment should be considered when CAGTA titers are increasing in critically ill patients.

Citing Articles

Anti-Candida Antibodies of Patients with Invasive Candidiasis Inhibit Growth, Alter Cell Wall Structure, and Kill Candida albicans In Vitro.

Carrano G, Arrieta-Aguirre I, Diez A, Bregon-Villahoz M, Fernandez-de-Larrinoa I, Moragues M Mycopathologia. 2024; 189(1):16.

PMID: 38324097 PMC: 10850236. DOI: 10.1007/s11046-023-00819-w.

Biomarkers of fungal infection: Expert opinion on the current situation.

Bouza E, Almirante B, Garcia Rodriguez J, Garnacho-Montero J, Salavert M, Munoz P Rev Esp Quimioter. 2019; 33(1):1-10.

PMID: 31729203 PMC: 6987620.

Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.

Pini P, Bettua C, Orsi C, Venturelli C, Forghieri F, Bigliardi S Infection. 2015; 44(2):223-33.

PMID: 26475482 DOI: 10.1007/s15010-015-0849-8.

β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis.

Martin-Mazuelos E, Loza A, Castro C, Macias D, Zakariya I, Saavedra P Intensive Care Med. 2015; 41(8):1424-32.

PMID: 26134359 DOI: 10.1007/s00134-015-3922-y.

Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patients.

Peman J, Zaragoza R, Quindos G, Alkorta M, Cuetara M, Camarena J BMC Infect Dis. 2011; 11:60.

PMID: 21388550 PMC: 3061907. DOI: 10.1186/1471-2334-11-60.

References

Zaragoza R, Peman J, Quindos G, Iruretagoyena J, Cuetara M, Ramirez P . Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clin Microbiol Infect. 2009; 15(6):592-5. DOI: 10.1111/j.1469-0691.2009.02794.x. View

Garey K, Rege M, Pai M, Mingo D, Suda K, Turpin R . Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006; 43(1):25-31. DOI: 10.1086/504810. View

Moragues M, Ortiz N, Iruretagoyena J, Garcia-Ruiz J, Amutio E, Rojas A . [Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis]. Enferm Infecc Microbiol Clin. 2004; 22(2):83-8. DOI: 10.1016/s0213-005x(04)73039-6. View

Gibot S . Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care. 2005; 9(5):485-9. PMC: 1297602. DOI: 10.1186/cc3732. View

Quindos G, Moragues M, Ponton J . Is there a role for antibody testing in the diagnosis of invasive candidiasis?. Rev Iberoam Micol. 2004; 21(1):10-4. View

Bromuro C, La Valle R, Sandini S, Urbani F, Ausiello C, Morelli L . A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun. 1998; 66(5):2154-62. PMC: 108176. DOI: 10.1128/IAI.66.5.2154-2162.1998. View

Morrell M, Fraser V, Kollef M . Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49(9):3640-5. PMC: 1195428. DOI: 10.1128/AAC.49.9.3640-3645.2005. View

Salesa R, Moragues M, Sota R, Peman J, Quindos G, Ponton J . Specific antibody response in a patient with Candida dubliniensis fungemia. Rev Iberoam Micol. 2004; 18(1):42-4. View

Zaragoza R, Peman J . Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol. 2006; 23(2):59-63. DOI: 10.1016/s1130-1406(06)70014-6. View

10.

Montagnoli C, Sandini S, Bacci A, Romani L, La Valle R . Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis. Med Mycol. 2004; 42(4):319-24. DOI: 10.1080/13693780310001644653. View

11.

Iruretagoyena J, Regulez P, Quindos G, Ponton J . Antibodies to Candida albicans germ tubes in two intensive care patients with invasive candidiasis. Rev Iberoam Micol. 2005; 17(3):93-6. View